Using minimised randomisation , we randomly assigned patients ( 1:1 ; minimised for age , sex , and immunological risk ) to either alemtuzumab-based induction treatment ( ie , alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids ) or basiliximab-based induction treatment ( basiliximab followed by standard-dose tacrolimus , mycophenolate , and prednisolone ) .